Team

Oncology Commercial Services Team

CHAIRMAN – DR NICK PLOWMAN, MA, MD, FRCR, FRCP

Senior Clinical Oncologist to St Bartholomew’s Hospital and The Hospital for Sick Children Great Ormond Street. Dr P N Plowman qualified from Cambridge University with a double first in medical sciences and natural sciences and has been a consultant oncologist at St Bartholomew’s Hospital and the Hospital for Sick Children in London for thirty years. His research work has led to the introduction of aromatase inhibitors into breast cancer management and glucocorticoids into advanced prostate cancer management, thereby making significant advantages and changes in best standard care to these two common important cancers. Dr Plowman has forwarded the practice of modern radiotherapy (for example, in children) and will shortly be part of a team introducing Linac-based proton beam radiotherapy into clinical practice. The introduction of lower cost Linacbased proton beam therapy will facilitate more widespread adoption of proton beam radiotherapy and the Linac-based proton system has the capability of performing “Flash” treatments. Dr Plowman has spearheaded focal radiation techniques in this country (Gamma Knife and Cyberknife). Dr Plowman researches and writes on CTCs and EMT. In recent years Dr Plowman has made significant contribution to genomically targeted therapy of cancer and currently advises two genomics companies – including research into liquid biopsy approaches to predictive testing for genome based therapy. His laboratory research into clinical radiosensitivity syndromes has contributed to a test for such hypersensitivity (H2AX assay) and the discovery of two new syndromes (xeroderma pigmentosa Complementation group C mutation and DNA ligase 4 mutation). The manipulation of DNA repair as a therapeutic target in cancer will surely assume greater importance in the future – and PARP inhibitors in BRCA mutant tumours is testimony to this approach. Further investigation of DNA repair will have increasing relevance to cancer therapies.

CHEEGEE SEE, PHD

25+ years of industry experience in big pharma (GSK, Roche) and SME biotechs (Proteome Sciences, Global Gene Corp, Trajecture) with an excellent working network of C-level decision-makers. Deep oncology clinical trial expertise – Clinical biomarker and experimental medicine leader for Roche’s Herceptin Phase 3 registration trial (ToGA study) for gastric cancer, 2006-2011. Deep oncology discovery research and drug development – Head of Translational Medicine at Global Gene Corp developing novel drug for prostate cancer, 2017. Deep expertise in Precision Medicines, companion diagnostics and biomarker technologies in multiple therapeutic areas – Global Head of Personalized Medicine at Proteome Sciences, 2013-2016. Published book chapter, November 2019 – ‘Clinical Strategies for Developing Next-Generation Cancer Precision Medicines’. Visiting professor at the University of Surrey, teaching MSc module in ‘Pharmaceutical Medicine’, 2015. CheeGee is a visionary strategist who is passionate about translating medical knowledge into transformative treatment options and creating strong and sustainable commercial value.

NATHAN NAGEL

Mr Nathan Nagel is a serial entrepreneur with 21 years’ experience on the commercial side of medicine. He has led OCS for the last eight years and provided big pharma, big med-tech and big-software PLCs with oncology support services. His executive experience includes CEO at Middle East Medical Portal Ltd, CEO at Gamlen Tableting Ltd, Board Adviser at the Mayfair Biohub Ltd, Interim Managing Director of the US liver disease CRO Sanyal Bio LLC, interim CEO of the neuroscience biotechnology company Neuro-Bio Ltd and CEO of the market research company Oncology Pharma Ltd. In parallel to leading Oncology Pharma Ltd Nathan was managing partner of LifeScience Ventures Ltd, a UK consulting company. Prior to leading companies, Nathan worked for Bayer Diagnostics and Takeda Pharmaceuticals, where he started his career.

CHARLENE SEXTON

Charlene is an oncology clinical trials manager. She has spent over 20 years in the Biotech industry as a Clinical Trial Manager for Global studies mostly focused in oncology. She has extensive connections both with the medical and scientific research communities in North-America and has developed many strong working relationships with Key Opinion Leaders. In addition, she is a passionate entrepreneur supporting Startup companies focused on Personalized Medicine technologies